Ambry Genetics Launches GenomeNext™ Whole Genome Sequencing Solution to Close the Rare Disease Diagnosis Gap

Ambry Genetics has announced the launch of GenomeNext™, a whole genome sequencing (WGS) test solution aimed at improving diagnostic outcomes for patients living with rare diseases. The announcement, made on October 13, 2026, positions Ambry as a direct competitor in the growing clinical WGS segment, a market that has seen accelerating demand as rare disease workflows increasingly move beyond targeted gene panels toward broader, more comprehensive genomic interrogation.

The Technology

GenomeNext™ represents Ambry's entry into clinical-grade whole genome sequencing as a diagnostic product, distinct from the exome-focused and panel-based offerings that have historically dominated rare disease testing. Whole genome sequencing captures both coding and non-coding regions of the genome, giving clinicians visibility into variant classes — including structural variants, deep intronic variants, and repeat expansions — that are systematically invisible to exome sequencing and entirely outside the scope of targeted panels. For rare disease patients who have already undergone standard-of-care testing without receiving a diagnosis, this broader interrogation represents a meaningful second chance at answers. Ambry's decision to package WGS as a defined "test solution" rather than a research-adjacent service signals the company's intent to make whole genome sequencing operationally accessible within clinical and health system environments.

Clinical Context

The rare disease diagnostic landscape has long been defined by what is often described as a diagnostic odyssey — years of inconclusive testing, multiple specialists, and significant emotional and financial burden for affected families. Targeted gene panels remain the first-line tool in many clinical settings due to their lower cost and faster turnaround, but their limitations are well documented. Patients with negative panel results frequently fall through the cracks of the current testing paradigm. Whole genome sequencing has demonstrated substantially higher diagnostic yields in published literature, particularly in pediatric neurology, metabolic disease, and immunodeficiency cohorts, and health systems in Singapore, the United Kingdom, and several U.S. academic medical centers have already begun integrating WGS into routine rare disease pathways. GenomeNext™ arrives as payer coverage for WGS gradually expands and as clinical utility evidence continues to accumulate, making this a strategically well-timed product entry for Ambry.

What's Next

The competitive implications of GenomeNext™ will become clearer as Ambry discloses reimbursement strategy, turnaround benchmarks, and the bioinformatics infrastructure underpinning the interpretation pipeline. Key questions for the field include how Ambry will handle variants of uncertain significance at the genome-wide scale and what clinical decision support tools will accompany the raw sequencing output. As whole genome sequencing edges closer to becoming a standard diagnostic option rather than a last resort, launches like GenomeNext™ will accelerate the industry-wide reckoning with how clinical laboratories operationalize, report, and reimburse the most comprehensive genetic test available.